Literature DB >> 19725892

The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis.

Jérôme Boursier1, Julien Vergniol, Apollinaire Sawadogo, Taoufiq Dakka, Sophie Michalak, Yves Gallois, Véronique Le Tallec, Frédéric Oberti, Isabelle Fouchard-Hubert, Nina Dib, Marie Christine Rousselet, Anselme Konaté, Naïma Amrani, Victor de Ledinghen, Paul Calès.   

Abstract

BACKGROUND AND AIMS: Blood tests and liver stiffness evaluation (LSE) by ultrasonographic elastometry are accurate tools for diagnosing liver fibrosis. We evaluated whether their synchronous combination in new scores could improve the diagnostic accuracy and reduce liver biopsy requirement in algorithm.
METHODS: Three hundred and ninety patients with chronic liver disease of miscellaneous causes were included. Five blood fibrosis tests were evaluated: APRI, FIB-4, Hepascore, Fibrotest and FibroMeter. The reference was fibrosis Metavir staging.
RESULTS: Diagnosis of significant fibrosis (Metavir F>or=2). The most accurate synchronous combination was FibroMeter+LSE, which provided a significantly higher area under the receiver operating characteristic curve (0.892) than LSE alone (0.867, P=0.011) or Fibrometer (0.834, P<10(-3)). An algorithm using the FibroMeter+LSE combination and then a liver biopsy in indeterminate cases had 91.9% diagnostic accuracy and required significantly fewer biopsies (20.2%) than previously published Bordeaux algorithm (28.6%, P=0.02) or sequential algorithm for fibrosis evaluation (SAFE) (55.7%, P<10(-3)). The Angers algorithm performance was not significantly different between viral hepatitis and other causes. Diagnosis of cirrhosis. The most accurate synchronous combination was LSE+FibroMeter, which provided >or=90% predictive values for cirrhosis in 90.6% of patients vs 87.4% for LSE (P=0.02) and 57.9% for FibroMeter (P<10(-3)). An algorithm including the LSE+FibroMeter combination, and then a liver biopsy in indeterminate cases, had a significantly higher diagnostic accuracy than the SAFE algorithm (91.0 vs 79.8%, P<10(-3)), and required significantly fewer biopsies than the Bordeaux algorithm (9.3 vs 25.3%, P<10(-3)).
CONCLUSION: The synchronous combination of a blood test plus LSE improves the accuracy of the non-invasive diagnosis of liver fibrosis and, consequently, markedly decreases the biopsy requirement in the diagnostic algorithm, notably to <10% in cirrhosis diagnosis.

Entities:  

Mesh:

Year:  2009        PMID: 19725892     DOI: 10.1111/j.1478-3231.2009.02101.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  25 in total

1.  Noninvasive Biomarkers of Liver Fibrosis: Clinical Applications and Future Directions.

Authors:  Daniel L Motola; Peter Caravan; Raymond T Chung; Bryan C Fuchs
Journal:  Curr Pathobiol Rep       Date:  2014-12-01

2.  FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Authors:  Keyur Patel; Mireen Friedrich-Rust; Yoav Lurie; Mircea Grigorescu; Carol Stanciu; Chuan-Mo Lee; Eugene R Schiff; Dieter Häussinger; Michael P Manns; Guido Gerken; Isabelle Colle; Michael Torbenson; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Stefan Zeuzem
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

3.  Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.

Authors:  Toshihide Shima; Kyoko Sakai; Hirohisa Oya; Takayuki Katayama; Yasuhide Mitsumoto; Masayuki Mizuno; Yoshihiro Kanbara; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2019-09-19       Impact factor: 7.527

4.  Non-invasive assessment of liver fibrosis in chronic hepatitis C.

Authors:  Laurent Castera
Journal:  Hepatol Int       Date:  2011-01-20       Impact factor: 6.047

5.  Magnetic resonance elastography of the kidneys: feasibility and reproducibility in young healthy adults.

Authors:  Olivier Rouvière; Rémi Souchon; Gaële Pagnoux; Jean-Michel Ménager; Jean-Yves Chapelon
Journal:  J Magn Reson Imaging       Date:  2011-07-18       Impact factor: 4.813

Review 6.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

Review 7.  Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.

Authors:  Chavdar S Pavlov; Giovanni Casazza; Dimitrinka Nikolova; Emmanuel Tsochatzis; Andrew K Burroughs; Vladimir T Ivashkin; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2015-01-22

Review 8.  Chronic hepatitis C and liver fibrosis.

Authors:  Giada Sebastiani; Konstantinos Gkouvatsos; Kostas Pantopoulos
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

9.  Combining hepatic surface nodularity and serum tests better predicts hepatic fibrosis stages in chronic liver disease.

Authors:  Hyo Jung Cho; Jaewon Choi; Bohyun Kim; JeongGil Ko; Joon-Il Choi; Jimi Huh; Jei Hee Lee; Jai Keun Kim
Journal:  Abdom Radiol (NY)       Date:  2021-05-12

10.  Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.

Authors:  Dana Crisan; Corina Radu; Monica Lupsor; Zeno Sparchez; Mircea Dan Grigorescu; Mircea Grigorescu
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.